TheraRadar
Landscape → Oncology

Lung Cancer (General) Clinical Trial Landscape

Data updated: May 20, 2026

1,289 clinical trials tracked since 2008

Lung cancer refers to a group of diseases in which cells in the lung grow uncontrollably and can spread to other parts of the body. It is a leading cause of cancer-related deaths worldwide. As of 2008, 1,284 clinical trials have been registered for lung cancer, with 563 trials currently active, meaning they are recruiting, enrolling, or active but not recruiting. The majority of active trials are in Phase 1 and Phase 2, with 223 and 347 trials respectively, compared to 76 in Phase 3 and 11 in Phase 4. This suggests a strong focus on early-stage drug development and investigation of novel therapeutic approaches. Chongqing Precision Biotech Co., Ltd is the leading industry sponsor with 9 active trials. AstraZeneca, Avistone Biotechnology Co., Ltd., GSK, and Pfizer are also prominent sponsors, with 6, 6, 5, and 5 active trials respectively.

559 active
/
1289 total (since 2008)
221
Phase 1 Active
534 total
347
Phase 2 Active
773 total
75
Phase 3 Active
166 total
11
Phase 4 Active
28 total

Top Industry Sponsors

Sorted by active Active Done Failed
Chongqing Precision Biotech Co., Ltd 9 0 0
AstraZeneca 6 8 1
Avistone Biotechnology Co., Ltd. 6 0 0
Pfizer 5 3 4
GSK 4 7 6

+ 10 more sponsors — see full table below

Featured Phase 3 Trials

NCT04181060 RECRUITING
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
National Cancer Institute (NCI) n=300
NCT06732401 ACTIVE NOT RECRUITING
Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer
National Cancer Institute (NCI) n=630
NCT04214262 ACTIVE NOT RECRUITING
Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer
National Cancer Institute (NCI) n=480
NCT06151574 ACTIVE NOT RECRUITING
Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
Boehringer Ingelheim n=428
NCT03793179 ACTIVE NOT RECRUITING
Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer
National Cancer Institute (NCI) n=600

+ 161 more Phase 3 trials — see full database below

Lung Cancer (General) — Trials Started by Year (last 10 years)

2016
47
2017
69
2018
65
2019
55
2020
88
2021
105
2022
90
2023
93
2024
132
2025
107
2026
61

TheraRadar.com

Full Trial Database

Complete sponsor table, every trial across all phases, plus competitive analytics. Sortable, filterable, exportable for Pro users.

Top Sponsors (all-time)

Chongqing Precision Biotech Co., Ltd
9
AstraZeneca
15
Avistone Biotechnology Co., Ltd.
6
Pfizer
12
GSK
17
Jiangsu HengRui Medicine Co., Ltd.
7
Roche
5
Daiichi Sankyo
5
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
3
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
3

Active Trials by Phase

Phase 1
221
Phase 2
347
Phase 3
75
Phase 4
11

Enrollment Size Distribution

1-50
618
51-200
391
201-500
130
501-1k
44
1k+
22

All Industry Sponsors

Sorted by active Active Done Failed
Chongqing Precision Biotech Co., Ltd 9 0 0
AstraZeneca 6 8 1
Avistone Biotechnology Co., Ltd. 6 0 0
Pfizer 5 3 4
GSK 4 7 6
Jiangsu HengRui Medicine Co., Ltd. 3 2 2
Roche 3 2 0
Daiichi Sankyo 3 0 2
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. 3 0 0
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) 3 0 0
Tango Therapeutics, Inc. 3 0 0
Sichuan Baili Pharmaceutical Co., Ltd. 3 0 0
BioNTech SE 3 0 0
A2 Biotherapeutics Inc. 3 0 0
Bristol-Myers Squibb 2 12 4
NCT04181060 RECRUITING
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
National Cancer Institute (NCI) n=300
NCT06732401 ACTIVE NOT RECRUITING
Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer
National Cancer Institute (NCI) n=630
NCT04214262 ACTIVE NOT RECRUITING
Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer
National Cancer Institute (NCI) n=480
NCT06151574 ACTIVE NOT RECRUITING
Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
Boehringer Ingelheim n=428
NCT03793179 ACTIVE NOT RECRUITING
Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer
National Cancer Institute (NCI) n=600
NCT06498635 RECRUITING
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
National Cancer Institute (NCI) n=306
NCT04267848 RECRUITING
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
National Cancer Institute (NCI) n=1,210
NCT02453282 ACTIVE NOT RECRUITING
Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)
AstraZeneca n=1,118
NCT06793215 RECRUITING
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Hoffmann-La Roche n=600
NCT06096844 RECRUITING
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
National Cancer Institute (NCI) n=304
NCT07185997 RECRUITING
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
ArriVent BioPharma, Inc. n=480
NCT06632327 RECRUITING
Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer
Alliance for Clinical Trials in Oncology n=1,100
NCT06500481 RECRUITING
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
NRG Oncology n=115
NCT06616584 RECRUITING
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
SWOG Cancer Research Network n=378
NCT07128199 ACTIVE NOT RECRUITING
A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
Taiho Oncology, Inc. n=360
NCT07005128 RECRUITING
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
Amgen n=330
NCT04841811 ACTIVE NOT RECRUITING
MDT-bridged Radical Therapy After Aumolertinib Introduction and Followed by MRD-guided Maintained Therapy for EGFR-mutated Unresectable Stage III NSCLC (APPROACH/CTONG2101)
Guangdong Association of Clinical Trials n=192
NCT04804644 RECRUITING
Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking Ability
NRG Oncology n=200
NCT06500455 RECRUITING
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
NRG Oncology n=269
NCT05624996 RECRUITING
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
NRG Oncology n=474
NCT04092283 ACTIVE NOT RECRUITING
Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer
National Cancer Institute (NCI) n=660
NCT03811002 ACTIVE NOT RECRUITING
Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)
National Cancer Institute (NCI) n=544
NCT06281964 ENROLLING BY INVITATION
Efficacy and Safety Evaluation of PLB1004 in Patients With Non-squamous NSCLC Harboring EGFR Exon 20 Insertion.
Avistone Biotechnology Co., Ltd. n=327
NCT07218146 RECRUITING
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
Zai Lab (Shanghai) Co., Ltd. n=480
NCT07222566 RECRUITING
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Pfizer n=1,410
NCT07502300 NOT YET RECRUITING
A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer(PANKU-Lung07)
Sichuan Baili Pharmaceutical Co., Ltd. n=562
NCT06497556 ACTIVE NOT RECRUITING
A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer
Hoffmann-La Roche n=338
NCT05633602 ACTIVE NOT RECRUITING
Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study
SWOG Cancer Research Network n=838
NCT03637816 ACTIVE NOT RECRUITING
Anamorelin Hydrochloride in Reducing Anorexia in Patients With Advanced Non-small Cell Lung Cancer
M.D. Anderson Cancer Center n=25
NCT06698042 ACTIVE NOT RECRUITING
A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)
Merck Sharp & Dohme LLC n=67
NCT07499674 RECRUITING
Evaluation of the Safety and Efficacy of Abenacianine (VGT-309) to Identify Cancer in Subjects Undergoing Surgery for Cancer in the Lung
Vergent Bioscience, Inc. n=132
NCT03391869 ACTIVE NOT RECRUITING
Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer
M.D. Anderson Cancer Center n=339
NCT04093167 RECRUITING
Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer
Canadian Cancer Trials Group n=230
NCT05091567 ACTIVE NOT RECRUITING
A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer
Hoffmann-La Roche n=660
NCT05499390 ACTIVE NOT RECRUITING
AK112 in Advanced Non-Small Cell Lung Cancer
Akeso n=398
NCT04428905 ACTIVE NOT RECRUITING
Self-Management Survivorship Care in Stage I-III Non-small Cell Lung Cancer or Colorectal Cancer
City of Hope Medical Center n=403
NCT06712355 RECRUITING
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
BioNTech SE n=621
NCT06563388 RECRUITING
Stereotactic Ablative Radiotherapy (SABR) for the Treatment of Patients With Metastatic Cancer, ID-COMET Trial
Roswell Park Cancer Institute n=800
NCT04871412 RECRUITING
The Thoracic Peri-Operative Integrative Surgical Care Evaluation Trial - Stage III
Ottawa Hospital Research Institute n=20
NCT07289646 NOT YET RECRUITING
Functional Lung Avoidance Planning Guided by Lung Perfusion PET/CT Versus Anatomical Planning for Lung Stereotactic Body Radiotherapy
University Hospital, Brest n=418
NCT07213375 RECRUITING
High Dose Dexamethasone to Reduce Postoperative Pain After Video-Assisted Thoracoscopic Surgery Lobectomy /Segmentectomy
Rigshospitalet, Denmark n=80
NCT07189455 RECRUITING
Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer
Suzhou Zelgen Biopharmaceuticals Co.,Ltd n=420
NCT06211036 ACTIVE NOT RECRUITING
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab
Amgen n=563
NCT06851663 RECRUITING
Trop2-targeted immunoPET Imaging of Solid Tumors
RenJi Hospital n=400
NCT05690945 ACTIVE NOT RECRUITING
A Study of QL1706 in Combination With Chemotherapy in PD-L1-Negative Non-small Cell Lung Cancer
Qilu Pharmaceutical Co., Ltd. n=606
NCT04655976 ACTIVE NOT RECRUITING
Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy
GlaxoSmithKline n=758
NCT04547504 ACTIVE NOT RECRUITING
PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 ≥ 50 %
University Hospital, Brest n=349
NCT06472076 ACTIVE NOT RECRUITING
A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)
GlaxoSmithKline n=88
NCT06457906 RECRUITING
SRS/SRT/Hypo-RT Versus HA-WBRT for No More Than 10 Brain Metastases in SCLC
Cancer Institute and Hospital, Chinese Academy of Medical Sciences n=340
NCT05692999 RECRUITING
Maintenance Pembrolizumab at Usual or Low doSE in Non-squamous Lung Cancer: a Non-inferiority Study
Gustave Roussy, Cancer Campus, Grand Paris n=1,166
NCT05078047 RECRUITING
Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO
UNICANCER n=646
NCT03390686 ACTIVE NOT RECRUITING
A Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin® in Advanced Non-squamous Non-small Cell Lung Cancer Patients
Prestige Biopharma Limited n=650
NCT06598527 RECRUITING
Stereotactic Body Radiotherapy Followed by Tislelizumab Plus Platinum-based Chemotherapy Versus Tislelizumab Plus Platinum-based Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Stage Ⅱ-Ⅲ Non-small Cell Lung Cancer: A Phase Ⅲ, Randomized, Multicenter, Prospective Study
Yang Hong n=360
NCT02785952 ACTIVE NOT RECRUITING
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
SWOG Cancer Research Network n=275
NCT06970782 NOT YET RECRUITING
Vebreltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFRm, MET+, Locally Advanced or Metastatic NSCLC Following EGFR-TKI Failure
Avistone Biotechnology Co., Ltd. n=278
NCT06968221 RECRUITING
Bovine Reinforcement in Stomach, Colorectal and Lung Operation
Shanghai Cingularbio Co. Ltd n=172
NCT05096663 ACTIVE NOT RECRUITING
Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
SWOG Cancer Research Network n=82
NCT06332274 RECRUITING
tislelizUMaB in canceR Patients With molEcuLar residuaL Disease
Gustave Roussy, Cancer Campus, Grand Paris n=717
NCT06416410 RECRUITING
JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation
Allist Pharmaceuticals, Inc. n=392
NCT06127654 RECRUITING
Ventilation Imaging to Improve the Quality of Life for Patients With Lung Cancer Treated With Radiation Therapy
University of Sydney n=165
NCT01394679 NOT YET RECRUITING
A Phase 3 Study of 99mTC-EC-DG SPECT/CT Versus PET/CT in Lung Cancer
Cell>Point LLC n=154
NCT06789796 NOT YET RECRUITING
a Study of QL1706 or QL1604 in Patients With Limited-stage Small Cell Lung Cancer After Chemoradiotherapy.
Qilu Pharmaceutical Co., Ltd. n=636
NCT06607796 RECRUITING
Efficacy and Safety of Intratumoral Toluenesulfonamide (PTS) Injection in Stage IV Driver Gene-Negative NSCLC With/Without Chemoimmunotherapy
Zhou Chengzhi n=180
NCT05055908 RECRUITING
Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint Inhibitors
Hunan Province Tumor Hospital n=12,000
NCT06526624 NOT YET RECRUITING
A Study of HS-20093 vs Active Surveillance in Limited-Stage Small Cell Lung Cancer
Hansoh BioMedical R&D Company n=406
NCT06478108 RECRUITING
Interventional Software for Multi-immunotherapy of Solid Tumors
Second Affiliated Hospital of Guangzhou Medical University n=60
NCT03755739 RECRUITING
Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors
Second Affiliated Hospital of Guangzhou Medical University n=200
NCT03632603 RECRUITING
PAlliative RAdioTherapy to Lung Cancer A Randomized Multicentre Phase III Study
University of Aarhus n=1,184
NCT06323148 NOT YET RECRUITING
Adjuvant Target Therapy Guided by ctDNA-MRD in Patients With EGFR-mutant II-IIIA Non-small Cell Lung Cancer (ECTOP-1022)
Fudan University n=226
NCT05085028 RECRUITING
A Randomised Open-label Phase III Trial of REduced Frequency Pembrolizumab immuNothErapy for First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
Imperial College London n=1,750
NCT06230445 RECRUITING
Effects of Digital Therapeutic in Whole Process Management of Lung Cancer
Sun Yat-sen University n=900
NCT06102161 NOT YET RECRUITING
Wedge Resection for Ground-glass Opacity-featured Lung Cancer (ECTOP-1020)
Fudan University n=286
NCT06048315 NOT YET RECRUITING
A Single Center, Single Arm Clinical Study on the Treatment of Advanced Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations and Failed EGFR TKIs With the Combination of Enrotinib and Paclitaxel Monoclonal Antibody
Degan Lu n=52
NCT02448992 RECRUITING
Hippocampal-Sparing Prophylactic Cranial Irradiation in Pathologically Nodal Positive Non-Small-Cell Lung Cancer
Chang Gung Memorial Hospital n=90
NCT04316364 RECRUITING
A Trial of SHR-1316/Placebo in Combination With Chemotherapy in Patients With Resectable NSCLC
Jiangsu HengRui Medicine Co., Ltd. n=537
NCT04929041 SUSPENDED
Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative
National Cancer Institute (NCI) n=427
NCT04475939 COMPLETED
Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-Small Cell Lung Cancer
GlaxoSmithKline n=666
NCT04702009 COMPLETED
Efficacy and Safety of First-line Anti-PD-1/PD-L1 Monoclonal Antibody in Combination With Chemotherapy and Bronchoscopy-assisted Interventional Therapy in Patients With Advanced Central Non-small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China n=33
NCT02973789 COMPLETED
Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)
NovoCure GmbH n=291
NCT03088540 COMPLETED
Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)
Regeneron Pharmaceuticals n=712
NCT04738487 COMPLETED
Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003)
Merck Sharp & Dohme LLC n=1,264
NCT05061823 COMPLETED
Bintrafusp Alfa Program Rollover Study
EMD Serono Research & Development Institute, Inc. n=22
NCT05223647 TERMINATED
Chemo-immunotherapy Plus Thoracic Radiotherapy in Extensive Stage Small-cell Lung Cancer
Norwegian University of Science and Technology n=239
NCT04619433 TERMINATED
A Study to Evaluate SHR-1210 in Combination With Famitinib Plus Chemotherapy in Subjects With NSCLC.
Jiangsu HengRui Medicine Co., Ltd. n=48
NCT04616768 COMPLETED
PROStep: A Feasibility Trial Using PROs and Step Data to Monitor Patients With Lung and GI Cancers
Abramson Cancer Center at Penn Medicine n=108
NCT03867175 COMPLETED
Immunotherapy With or Without SBRT in Patients With Stage IV Non-small Cell Lung Cancer
Wake Forest University Health Sciences n=5
NCT04588246 TERMINATED
Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery
NRG Oncology n=19
NCT02754882 COMPLETED
A Study Comparing SB8 and Avastin® in Patients With Advanced Non-squamous Non-small Cell Lung Cancer
Samsung Bioepis Co., Ltd. n=763
NCT02578680 COMPLETED
Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)
Merck Sharp & Dohme LLC n=616
NCT02129699 TERMINATED
Survival imProvement in Lung cancEr iNduced by DenOsUmab theRapy
ETOP IBCSG Partners Foundation n=595
NCT01996098 TERMINATED
Icotinib Following Chemotherapy Versus Chemotherapy as Adjuvant Therapy in Stage IIA-IIIA NSCLC With EGFR Mutation
Sun Yat-sen University n=251
NCT03195491 COMPLETED
A Study of Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Second-Line Nivolumab Monotherapy in Asia
Bristol-Myers Squibb n=400
NCT04902885 COMPLETED
Phase 3 Study Evaluating Efficacy, Safety and Pharmacokinetics of Trilaciclib In Small Cell Lung Cancer Patients
Jiangsu Simcere Pharmaceutical Co., Ltd. n=95
NCT04233476 COMPLETED
99mTc-3PRGD2 SPECT/CT for Integrin Imaging of Lung Cancer
RDO Pharm. n=409
NCT03950674 COMPLETED
Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)-Japan Extension Study
Merck Sharp & Dohme LLC n=40
NCT03866993 COMPLETED
A Study of Anti-PD-1 AK105 in Patients With Metastatic Squamous Non-small Cell Lung Cancer
Akeso n=350
NCT03866980 TERMINATED
A Study of Anti-PD-1 AK105 in Patients With Metastatic Nonsquamous Non-small Cell Lung Cancer
Akeso n=164
NCT02997501 COMPLETED
T790M Plasma Testing Methodology Comparison and Clinical Validation
AstraZeneca n=256
NCT04171284 TERMINATED
SCT-I10A or Placebo Plus Docetaxel With Previously Treated Squamous Cell Non-small Cell Lung Cancer
Sinocelltech Ltd. n=188
NCT04878016 COMPLETED
A Study of Carboplatin Plus Etoposide With or Without ZKAB001 (Anti-PD-L1 Antibody) in Patients With ES-SCLC
Lee's Pharmaceutical Limited n=498
NCT05318443 COMPLETED
A Study Exploring Efficacy of SIBP04 in Subjects With Non-squamous Non-small Cell Lung Cancer
Shanghai Institute Of Biological Products n=512
NCT03200236 COMPLETED
The Lung Screening, Tobacco and Health Project
Georgetown University n=1,114
NCT02864251 COMPLETED
A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy
Bristol-Myers Squibb n=367
NCT00795340 COMPLETED
Cediranib, Paclitaxel, and Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
NCIC Clinical Trials Group n=306
NCT01000025 COMPLETED
PF-00299804 in Stage IIIB or Stage IV Non-Small Cell Lung Cancer Not Responding to Standard Therapy for Advanced or Metastatic Cancer
NCIC Clinical Trials Group n=720
NCT02481830 COMPLETED
Effectiveness Study of Nivolumab Compared to Chemotherapy in Patients With Relapsed Small-cell Lung Cancer
Bristol-Myers Squibb n=569
NCT01107626 COMPLETED
Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
ECOG-ACRIN Cancer Research Group n=1,516
NCT03689634 COMPLETED
Move For Surgery - A Novel Preconditioning Program
St. Joseph's Healthcare Hamilton n=102
NCT03306992 COMPLETED
Precision-exercise-prescription for Lung Cancer Patients Undergoing Surgery: The PEP Study
University of Utah n=200
NCT02766335 COMPLETED
Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
SWOG Cancer Research Network n=116
NCT00946712 TERMINATED
S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer
SWOG Cancer Research Network n=1,333
NCT01257139 COMPLETED
Trial Involving Subjects Over 70 Years of Age With Non Small-cell Lung Cancer of Stage IV and Comparing a "Classical" Strategy of Treatment Allocation, With an"Optimized" Strategy Allocating the Same Treatments
Rennes University Hospital n=490
NCT04241315 COMPLETED
ELUCIDATE: Enabling Lung Cancer Identification Using Folate Receptor Targeting
On Target Laboratories, LLC n=112
NCT02713867 COMPLETED
A Dose Frequency Optimization,Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer Who Received Up to 12 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks
Bristol-Myers Squibb n=363
NCT05725343 TERMINATED
A Prevention Trial of Canakinumab in Subjects at High Risk for Lung Cancer
Mario Negri Institute for Pharmacological Research n=350
NCT03682224 COMPLETED
Exparel and Marcaine for Pain Management in Thoracoscopic Lobectomy Patients
Southern Illinois University n=57
NCT02538666 COMPLETED
An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based Chemotherapy
Bristol-Myers Squibb n=907
NCT00858364 TERMINATED
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Amgen n=2,549
NCT03870152 TERMINATED
Electrocautery Ablation for the Prevention of Lung Cancer
University College, London n=13
NCT02856581 TERMINATED
Management of Tobacco Treatment Intervention in Reducing Surgical Complications in Patients With Newly Diagnosed Lung Cancer Who Smoke Cigarettes
Alliance for Clinical Trials in Oncology n=23
NCT04342377 COMPLETED
The Canada Lymph Node Score Project: A Crossover Trial
St. Joseph's Healthcare Hamilton n=80
NCT01067144 TERMINATED
Stanford Accelerated Recovery Trial (START)
Stanford University n=422
NCT01207011 COMPLETED
Amrubicin (AMR) Trial in Patients With Non-small Cell Lung Cancer
Sumitomo Pharma Co., Ltd. n=202
NCT00687986 TERMINATED
Trial of Either Surgery or Stereotactic Radiotherapy for Early Stage (IA) Lung Cancer
Amsterdam UMC, location VUmc n=22
NCT01780675 COMPLETED
Hippocampus Avoidance PCI vs PCI
The Netherlands Cancer Institute n=168
NCT02474355 COMPLETED
Real World Treatment Study of AZD9291 for Advanced/Metastatic EGFR T790M Mutation NSCLC
AstraZeneca n=3,017
NCT02566993 COMPLETED
Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus CAV or Topotecan as Treatment in Patients With Small-Cell Lung Cancer
PharmaMar n=613
NCT02737501 COMPLETED
ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants
Ariad Pharmaceuticals n=275
NCT02965378 COMPLETED
Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer
SWOG Cancer Research Network n=43
NCT02785939 COMPLETED
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer
SWOG Cancer Research Network n=53
NCT02644252 TERMINATED
Tocotrienol as a Nutritional Supplement in Patients With Advanced Lung Cancer
Vejle Hospital n=79
NCT01244191 TERMINATED
Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer
Daiichi Sankyo n=1,048
NCT04237090 COMPLETED
Feasibility of a Clinical Trial Comparing the Use of Cetirizine to Replace Diphenhydramine in the Prevention of Reactions Related to Paclitaxel
Ciusss de L'Est de l'Île de Montréal n=27
NCT02361099 COMPLETED
SENTINEL : Impact of the Use of a Web-application for the Detection of Lung Cancer Relapse
Weprom n=133
NCT01285609 COMPLETED
Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and Carboplatin
Bristol-Myers Squibb n=1,289
NCT02926638 TERMINATED
Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
SWOG Cancer Research Network n=9
NCT01902823 TERMINATED
Effect of Cancer Nurse Navigators on Patient Outcomes
University of Wisconsin, Madison n=16
NCT02279732 COMPLETED
Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin
Bristol-Myers Squibb n=342
NCT03348904 TERMINATED
Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer
Incyte Corporation n=2
NCT03346304 WITHDRAWN
Photodynamic Therapy for the Prevention of Lung Cancer
University College, London
NCT03239171 COMPLETED
Bioinformation Therapy for Lung Cancer
Fuda Cancer Hospital, Guangzhou n=120
NCT01446874 TERMINATED
Prevention of Post-operative Pneumonia (POPP)
Washington University School of Medicine n=150
NCT03645018 COMPLETED
Lung Cancer Early Diagnosis With Digital Tomosynthesis: Re-evaluation of Lung Nodule Detection Rate at 5 Years
Ospedale Santa Croce-Carle Cuneo n=1,341
NCT03637335 TERMINATED
Comparing Palliative Radiotherapy With or Without Carboplatin
Institut Cancerologie de l'Ouest n=26
NCT01041781 TERMINATED
Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer
Alliance for Clinical Trials in Oncology n=313
NCT01208064 TERMINATED
Pazopanib Hydrochloride or a Placebo in Treating Patients With Non-Small Cell Lung Cancer Who Have Received First-Line Chemotherapy
European Organisation for Research and Treatment of Cancer - EORTC n=102
NCT03417037 WITHDRAWN
An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer
Bristol-Myers Squibb
NCT02134015 TERMINATED
Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)
Daiichi Sankyo n=145
NCT01154140 COMPLETED
A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung
Pfizer n=343
NCT01336894 TERMINATED
Surgery With or Without Internal Radiation Therapy Compared With Stereotactic Body Radiation Therapy in Treating Patients With High-Risk Stage I Non-Small Cell Lung Cancer
Alliance for Clinical Trials in Oncology n=13
NCT01999673 COMPLETED
Phase 3 Study of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Late-stage Non-squamous Non-small-cell Lung Cancer
Peregrine Pharmaceuticals n=582
NCT00863512 TERMINATED
Chemotherapy or Observation in Treating Patients With Early Stage Non-Small Cell Lung Cancer
Alliance for Clinical Trials in Oncology n=34
NCT01383148 TERMINATED
Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer
Transgene n=222
NCT01377376 TERMINATED
A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of ARQ 197 Plus Erlotinib Versus Placebo Plus Erlotinib
Kyowa Kirin Co., Ltd.
NCT02267096 COMPLETED
Lombardi Comprehensive Cancer Center/Legacy Pilot Study to Reduce Adverse Smoking Outcomes in the Context of Lung Cancer Screening
Georgetown University n=95
NCT01887795 COMPLETED
Phase Ⅲ Trial of WBRT Versus Erlotinib Concurrent Whole-brain Radiation Therapy as first-line Treatment for Patients With Multiple Brain Metastases From Non-small-cell Lung Cancer(ENTER): a Multicentre, Open-label, Randomised Study
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University n=224
NCT01082549 COMPLETED
Trial of Gemcitabine/Carboplatin With or Without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects With Previously Untreated Stage IV Squamous Non-Small-Cell Lung Cancer (NSCLC)
Sanofi n=780
NCT01310387 COMPLETED
Prospective Study of Active Pain Management in Lung Cancer Outpatients (APM)
Chonnam National University Hospital n=79
NCT01955824 COMPLETED
A Trial on Clinical Efficacy of 1% Versus 2% Lignocaine in Cough Suppression and Pain Relief in Patients Undergoing Flexible Bronchoscopy
Post Graduate Institute of Medical Education and Research, Chandigarh n=500
NCT01782053 COMPLETED
Communicating Smoking Risks Through Graphic Warning Labels
University of Pennsylvania n=245
NCT00660504 COMPLETED
Phase3 Study of Amrubicin With Cisplatin Versus Etoposide-cisplatin for Extensive Disease Small Cell Lung Cancer
Sumitomo Pharma (Suzhou) Co., Ltd. n=300
NCT01281787 COMPLETED
PREvention of Atrial Fibrillation in patientS Undergoing thorAcic surGEry for Lung Cancer
European Institute of Oncology n=320
NCT01028417 COMPLETED
Study to See if Microcoil Insertion Reduces the Rate of Open Thoracotomy for Removal of Lung Nodules
University of British Columbia n=60
NCT00801736 TERMINATED
ERCC1 Targeted Trial
University College, London n=648
NCT00522639 TERMINATED
Predictive Value of FDG-PET-CT Scans for Patients With Lung Cancer Receiving Concurrent Chemo-Radiation
Maastricht Radiation Oncology n=120
NCT04768075 COMPLETED
Camrelizumab Combined With SRT/WBRT and Chemotherapy in Patients With Brain Metastases of Driven Gene-negative NSCLC
Guangdong Association of Clinical Trials n=60

Full Lung Cancer (General) Pipeline

Every sponsor, every trial across Phase 1–4. Sortable, filterable, exportable.

Unlock with Pro

Data: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only